ERS Virtual International Congress 2021 - E-poster Advances in asthma treatment

Airway diseases

E-poster

Advances in asthma treatment Digital health

Aims : This session is built from abstracts published on the ERS Congress platform from 23 August, in an e-poster pdf format with a 3-minute audio narration. Participants and chairs of the session are invited to access all e-posters from 23 August to 4 September prior to the 1-hour live, online discussion scheduled from September 5-7. Please note that during live discussion there will be NO e-poster/abstract presentations, only discussion.

Methods : Endoscopy and interventional pulmonology, Surgery, Pulmonary function testing, Epidemiology, General respiratory patient care

Chairs

Virum (Denmark)

Athens (Greece)

Real-world treatment patterns of newly diagnosed patients with asthma and/or COPD A. Markus(Rotterdam, Netherlands)

Triple combination therapy in severe asthma: overview from the Italian Registry Severe Asthma (IRSA) C. Micheletto(S.Giovanni Lupatoto, Italy)

Annual systemic and inhaled corticosteroid exposures in US patients =4 years with asthma M. Lanz(Coral Gables, United States)

Mindfulness based cognitive therapy in poorly controlled asthma: Will patients attend and do they benefit? S. Smith(Newcastle, United Kingdom)

Bronchial Thermosplaty and severe asthma with frequent severe exacerbations : a controlled study. J. Leroux(Strasbourg, France)

Healthcare costs associated with short-acting ß2-agonist use in asthma: an observational UK study from the SABINA global programme D. Attar(London, United Kingdom)

Efficacy of different dosing regimens of azithromycin in a real-world severe asthma cohort A. Kumar(Sale, United Kingdom)

A preliminary study to identify correlations between blood glucose levels and cardiorespiratory observations in acute asthma patients receiving nebulised salbutamol. C. Mortimer(Sevenoaks (Kent), United Kingdom)

Oral corticosteroids-related comorbidities in severe asthma A. Vaghi(Bollate (MI), Italy)

Evaluation of Asthma control and oral corticosteroids in Severe Asthma C. Micheletto(S.Giovanni Lupatoto, Italy)

Implementation of a nursing led intervention bundle in the Emergency Department : Outcomes W. Lim(Singapore, Singapore)

Spirometric changes in bronchodilation tests as predictors of asthma diagnosis and treatment response in patients with FEV1 =80% predicted M. Zhang(上海市, China)

Use of health care and management of asthma patients in the emergency room during the COVID 19 pandemic: lessons for the next wave. S. Foulquier(Bruguières, France)

The effects of nebulised beta-2 agonists on clinical observations in asthma exacerbations: a systematic review C. Mortimer(Sevenoaks (Kent), United Kingdom)

Inhaled antibiotic therapy in patients with severe asthma E. AVALOS PEREZ-URRIA(Madrid , Spain)

Shared decision making in severe asthma therapy: qualitative study of physician-patient communication E. Lu(Philadelphia, United States)

Late Breaking Abstract - Response to mepolizumab in patients with severe CRSwNP using EUFOREA 2021 criteria V. Lund(London, United Kingdom)

Late Breaking Abstract - Two-year cumulative oral corticosteroid exposure in severe eosinophilic asthma before and after anti-IL-5 therapy J. Kroes(Leeuwarden, Netherlands)

Late Breaking Abstract - Early benefits in patient-reported outcomes (PROs) and physical activity (PA) in patients with severe eosinophilic asthma (SEA) treated with benralizumab: interim analysis of the imPROve Asthma study M. Lommatzsch(Rostock, Germany)

Late Breaking Abstract - International, prospective real-world study of mepolizumab in patients with severe asthma at one year: REALITI-A C. Pilette(Bruxelles, Belgium)